Stock Track | AKESO Soars 5.32% in Morning Session as Market Reassesses Ivonescimab Trial Interim Results

Stock Track

May 06

AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.

The upward movement represents a recovery following a previous sell-off triggered by news from partner Summit Therapeutics regarding an interim analysis of the global Phase III Harmoni-3 trial for ivonescimab. While the squamous NSCLC cohort initially failed to meet pre-specified statistical significance at the interim stage, market participants are now reassessing the implications, recognizing that this outcome does not constitute a clinical failure and that the study will proceed to its final analysis.

Institutional commentary has supported the rebound, with analysis suggesting that failing the stringent interim criteria does not preclude the drug from potentially outperforming Keytruda in the final analysis later in 2026. This renewed confidence, based on experience from related trials, is driving the stock's recovery from its recent declines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129022352"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129022352\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129022352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129022352","market":"nz","top_or_hot":-1,"title":"Stock Track | AKESO Soars 5.32% in Morning Session as Market Reassesses Ivonescimab Trial Interim Results","media":"Stock Track","content":"<p>AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.</p><p>The upward movement represents a recovery following a previous sell-off triggered by news from partner Summit Therapeutics regarding an interim analysis of the global Phase III Harmoni-3 trial for ivonescimab. While the squamous NSCLC cohort initially failed to meet pre-specified statistical significance at the interim stage, market participants are now reassessing the implications, recognizing that this outcome does not constitute a clinical failure and that the study will proceed to its final analysis.</p><p>Institutional commentary has supported the rebound, with analysis suggesting that failing the stringent interim criteria does not preclude the drug from potentially outperforming Keytruda in the final analysis later in 2026. This renewed confidence, based on experience from related trials, is driving the stock's recovery from its recent declines.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 5.32% in Morning Session as Market Reassesses Ivonescimab Trial Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 5.32% in Morning Session as Market Reassesses Ivonescimab Trial Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 10:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.</p><p>The upward movement represents a recovery following a previous sell-off triggered by news from partner Summit Therapeutics regarding an interim analysis of the global Phase III Harmoni-3 trial for ivonescimab. While the squamous NSCLC cohort initially failed to meet pre-specified statistical significance at the interim stage, market participants are now reassessing the implications, recognizing that this outcome does not constitute a clinical failure and that the study will proceed to its final analysis.</p><p>Institutional commentary has supported the rebound, with analysis suggesting that failing the stringent interim criteria does not preclude the drug from potentially outperforming Keytruda in the final analysis later in 2026. This renewed confidence, based on experience from related trials, is driving the stock's recovery from its recent declines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1129022352","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129022352","pubTimestamp":1778035771,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.The upward movement represents a recovery following a previous...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物早盘大涨5.32%市场重估Ivonescimab试验中期结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock price surged 5.32% during the morning trading session, marking a significant rebound for the biopharmaceutical company.The upward movement represents a recovery following a previous sell-off triggered by news from partner Summit Therapeutics regarding an interim analysis of the global Phase III Harmoni-3 trial for ivonescimab. While the squamous NSCLC cohort initially failed to meet pre-specified statistical significance at the interim stage, market participants are now reassessing the implications, recognizing that this outcome does not constitute a clinical failure and that the study will proceed to its final analysis.Institutional commentary has supported the rebound, with analysis suggesting that failing the stringent interim criteria does not preclude the drug from potentially outperforming Keytruda in the final analysis later in 2026. This renewed confidence, based on experience from related trials, is driving the stock's recovery from its recent declines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}